A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells

Biochemical Pharmacology

Volumn 97, Issue 1, 2015, Pages 51-61

  Yan, Jun ^a   Pang, Yanqing ^a   Sheng, Jianfeng ^a   Wang, Yali ^a   Chen, Jie ^a   Hu, Jinhui ^a   Huang, Ling ^a   Li, Xingshu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemical compounds studied in this article Combretastatin A 4 (PubChem CID:5351344); Cisplatinum (PubChem CID: 441203); Colchicine (PubChem CID: 6167); Taxol (PubChem CID: 36314); Vincristine (PubChem CID: 5978)

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BETA TUBULIN; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 2; CELL CYCLE PROTEIN 20; CELL CYCLE PROTEIN 25C; CISPLATIN; COLCHICINE; COMBRETASTATIN A4 DERIVATIVE; COMBRETASTATIN A4 PHOSPHATE; CYCLIN B1; PACLITAXEL; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VINCRISTINE; BENZODIAZEPINE DERIVATIVE; NEW DRUG; ORGANOPHOSPHATE; STILBENE DERIVATIVE; TUBULIN; TUBULIN MODULATOR;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CANCER SIZE; CELL CYCLE PROGRESSION; CELL DIVISION; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; EMBRYO; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; IC50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LIVER CANCER CELL LINE; LUNG CANCER; LUNG CANCER CELL LINE; M PHASE CELL CYCLE CHECKPOINT; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; MICROTUBULE; MOLECULAR DOCKING; NUDE MOUSE; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIAZEPINONES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULES; MOLECULAR DOCKING SIMULATION; ORGANOPHOSPHATES; RANDOM ALLOCATION; STILBENES; TUBULIN; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939572489     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.07.008     Document Type: Article

References (53)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA. Cancer J. Clin. 65 2015 5 29
2. B.V. Madhukar, and J.E. Trosko The causes of cancer: implications for prevention and treatment Indian J. Pediatr. 64 1997 131 141
3. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA. Cancer J. Clin. 60 2010 277 300
4. R. Siegel, C. DeSantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, and et al. Cancer treatment and survivorship statistics, 2012 CA Cancer J. Clin. 62 2012 220 241
5. W. Chen Cancer statistics: updated cancer burden in China Chin. J. Cancer Res. 27 2015 1
6. J.C. Zabala, and N.J. Cowan Tubulin dimer formation via the release of alpha- and beta-tubulin monomers from multimolecular complexes Cell Motil. Cytoskeleton. 23 1992 222 230
7. C.H. Aylett, J. Lowe, and L.A. Amos New insights into the mechanisms of cytomotive actin and tubulin filaments Int. Rev. Cell. Mol. Biol. 292 2011 1 71
8. P.K. Sorger, M. Dobles, R. Tournebize, and A.A. Hyman Coupling cell division and cell death to microtubule dynamics Curr. Opin. Cell Biol. 9 1997 807 814
9. T. Horio, and T. Murata The role of dynamic instability in microtubule organization Front. Plant Sci. 5 2014 511
10. M. Kavallaris Microtubules and resistance to tubulin-binding agents Nat. Rev. Cancer 10 2010 194 204
11. F. Pellegrini, and D.R. Budman Review: tubulin function, action of antitubulin drugs, and new drug development Cancer Invest. 23 2005 264 273
12. L.G. Wang, X.M. Liu, W. Kreis, and D.R. Budman The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review Cancer Chemother. Pharmacol. 44 1999 355 361
13. S. Honore, E. Pasquier, and D. Braguer Understanding microtubule dynamics for improved cancer therapy Cell Mol. Life Sci. 62 2005 3039 3056
14. R. Kaur, G. Kaur, R.K. Gill, R. Soni, and J. Bariwal Recent developments in tubulin polymerisation inhibitors: An overview Eur. J. Med. Chem. 87 2014 89 124
15. M.N. Islam, and M.N. Iskander Microtubulin binding sites as target for developing anticancer agents Mini Rev. Med. Chem. 4 2004 1077 1104
16. A. Jordan, J.A. Hadfield, N.J. Lawrence, and A.T. McGown Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle Med. Res. Rev. 18 1998 259 296
17. J.K. Pollock, N.K. Verma, N.M. O'Boyle, M. Carr, M.J. Meegan, and D.M. Zisterer Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway Biochem. Pharmacol. 92 2014 544 557
18. M. Henary, L. Narayana, S. Ahad, S.R. Gundala, R. Mukkavilli, V. Sharma, and et al. Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity Biochem. Pharmacol. 92 2014 192 205
19. E.A. Perez Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance Mol. Cancer Ther. 8 2009 2086 2095
20. G.R.G.M. Pettit Cragg, D.L. Herald, J.M. Schmidt, and P. Lohavanijaya Isolation and structure of combretastatin Can. J. Chem. 1982 1374 1376
21. G.J. Rustin, S.M. Galbraith, H. Anderson, M. Stratford, L.K. Folkes, L. Sena, and et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results J. Clin. Oncol. 21 2003 2815 2822
22. T. Meyer, A.M. Gaya, G. Dancey, M.R. Stratford, S. Othman, S.K. Sharma, and et al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas Clin. Cancer Res. 15 2009 4484 4492
23. G.J. Kang, Z. Getahun, A. Muzaffar, A. Brossi, and E. Hamel N-acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring. Evaluation of the mechanistic basis for their enhanced biological properties J. Biol. Chem. 265 1990 10255 10259
24. R.B. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, and M. Knossow Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 428 2004 198 202
25. D. Bonne, C. Heuséle, C. Simon, and D. Pantaloni 4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules J. Biol. Chem. 260 1985 2819 2825
26. J.F. Diaz, and J.M. Andreu Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition Biochemistry 32 1993 2747 2755
27. C.T. Chen, Y. Gan, J.L. Au, and M.G. Wientjes Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation Cancer Res. 58 1998 2777 2783
28. M. Luconi, and M. Mannelli Xenograft models for preclinical drug testing: Implications for adrenocortical cancer Mol. Cell. Endocrinol. 351 2012
29. G. Kremmidiotis, A.F. Leske, T.C. Lavranos, D. Beaumont, J. Gasic, A. Hall, and et al. BNC105: A novel tubulin polymerisation inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy Mol. Cancer Ther. 9 2010 1562 1573
30. P.D. Davis, G.J. Dougherty, D.C. Blakey, S.M. Galbraith, G.M. Tozer, A.L. Holder, and et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res. 62 2002 7247 7253
31. L. Vincent, P. Kermani, L.M. Young, J. Cheng, F. Zhang, K. Shido, and et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling J. Clin. Invest. 115 2005 2992 3006
32. A.T.M.M. Fojo Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR) Semin. Oncol. 32 2005 3 8
33. P.R. Clarke, and L.A. Allan Cell-cycle control in the face of damage - a matter of life or death Trends Cell Biol. 19 2009 89 98
34. H. Kiyokawa, and D. Ray In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets Anticancer Agents Med. Chem. 8 2008 832 836
35. C.A. Afshari, and J.C. Barrett Cell cycle controls: potential targets for chemical carcinogens Environ. Health Perspect. 101 Suppl. 5 1993 9 14
36. F. Mollinedo, and C. Gajate Microtubules, microtubule-interfering agents and apoptosis Apoptosis 8 2003 413 450
37. S. Haldar, A. Basu, and C.M. Croce Bcl2 is the guardian of microtubule integrity Cancer Res. 57 1997 229 233
38. M.S. Poruchynsky, E.E. Wang, C.M. Rudin, M.V. Blagosklonny, and T. Fojo Bcl-xl is phosphorylated in malignant cells following microtubule disruption Cancer Res. 58 1998 3331 3338
39. D.R.K. Green The Pathophysiology of Mitochondrial Cell Death Science 305 2004 626 629
40. J.J. Cai D. P. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss J. Biol. Chem. 273 1998 11401 11404
41. B. Zhao, and X. Li Altholactone induces reactive oxygen species-mediated apoptosis in bladder cancer T24 cells through mitochondrial dysfunction, MAPK-p38 activation and Akt suppression Oncol. Rep. 31 2014 2769 2775
42. Z. Sahenk, R. Barohn, P. New, and J.R. Mendell Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings Arch. Neurol. 51 1994 726 729
43. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1 1995 27 30
44. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat. Med. 6 2000 389 395
45. D. George, S.D. Yancopoulos, W. Nicholas Gale, S. John Rudge, J. Stanley Wiegand, and Jocelyn Holash Vascular-specific growth factors and blood vessel formation Nature 407 2000 242 248
46. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364
47. D.W. Siemann, D.J. Chaplin, and M.R. Horsman Vascular-targeting therapies for treatment of malignant disease Cancer 100 2004 2491 2499
48. M.A. Jordan, and L. Wilson Microtubules as a target for anticancer drugs Nat. Rev. Cancer 4 2004 253 265
49. F. Toyoshima-Morimoto, E.-N. Taniguchi Fau Shinya, N.-A. Shinya Fau Iwamatsu, A.-E. Iwamatsu Fau Nishida, and E. Nishida Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase Nature 410 2001 215 220
50. C. Jessus, and R. Ozon Function and regulation of cdc25 protein phosphate through mitosis and meiosis Prog. Cell Cycle Res. 1 1995 215 228
51. K.M. Murphy, V. Ranganathan, M.L. Fau-Farnsworth, Farnsworth ML, M. Fau-Kavallaris, M. Kavallaris, R.B. Fa-Lock, and R.B. Lock Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells Cell Death Differ. 7 2000 102 111
52. K. Yamamoto, H. Ichijo, S.J. Fau-Korsmeyer, and S.J. Korsmeyer BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M Mol. Cell. Biol. 19 1999 8469 8478
53. S. Zaman, R. Wang, and V. Gandhi Targeting the apoptosis pathway in hematologic malignancies Leukemia Lymphoma 55 2014 1980 1992